Cyramza ® (ramucirumab)

För fullständig produktresumé för Cyramza® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Cyramza® (ramucirumab): Extravasal infusion

Om extravasering inträffar eller misstänks, följ lokala anvisningar för hantering av icke-vesicant extravasal infusion.

Detailed Information

Ramucirumab is a nonvesicant as it is an antibody in a neutral formulation that is a specific receptor antagonist. No dedicated extravasation studies were conducted in animals. However, local tolerance was investigated in 2 repeat-dose toxicity evaluations in cynomolgus monkeys by clinical observations and as part of the histopathological evaluations. Intravenous administration of ramucirumab was well tolerated at all dose levels. Mild, local injection-site reactions were observed and consisted of mononuclear and/or polymorphonuclear cells in the perivascular areas.1

If extravasation occurs or is suspected, follow your local procedures for managing nonvesicant extravasation.

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Datum fӧr senaste ӧversyn 2019 M08 07


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss